TrialNeuro-oncology2017

Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.

Benjamin M Ellingson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.